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Abstract
Objective: To describe the rationale for a novel study design and baseline characteristics of a disease-modifying trial of isradipine 10 mg daily in early Parkinson disease (PD). Methods: STEADY-PDIII is a 36-month, Phase 3, parallel
group, placebo-controlled study of the efficacy of isradipine 10 mg daily in 336
participants with early PD as measured by the change in the Unified Parkinson
Disease Rating Scale (UPDRS) Part I-III score in the practically defined ON
state. Secondary outcome measures include clinically meaningful measures of
disability progression in early PD: (1) Time to initiation and utilization of
dopaminergic therapy; (2) Time to onset of motor complications; (3) Change
in nonmotor disability. Exploratory measures include global measures of functional disability, quality of life, change in the ambulatory capacity, cognitive
function, and pharmacokinetic analysis. Rationale for the current design and
alternative design approaches are discussed. Results: The entire cohort of 336
participants was enrolled at 55 Parkinson Study Group sites in North America.
The percentage of male participants were 68.5% with a mean age of 61.9 years
(sd 9.0), mean Hoehn and Yahr stage of 1.7 (sd 0.5), mean UPDRS total of
23.1 (sd 8.6), and MoCA of 28.1 (sd 1.4). Interpretation: STEADY-PD III has
a novel and innovative design allowing for the determination of longer duration
benefits on clinically relevant outcomes in a relatively small cohort on top of
the benefit derived from symptomatic therapy. Baseline characteristics are similar to those in previously enrolled de novo PD trials. This study represents a
unique opportunity to evaluate the potential impact of a novel therapy to slow
progression of PD disability and provide clinically meaningful benefits.

Introduction
Parkinson disease (PD) is a significant and increasing
public health issue. PD is the second most common
chronic neurodegenerative disease, after Alzheimer’s disease, affecting nearly 1% of the population over the age
of 65.1 The prevalence of PD is expected to double in the
360

next 20 years in the world’s most populous nations.2 The
economic burden of PD is estimated to be $23 billion
annually in US and projected to increase to $50 billion by
year 2040.3 Current therapy is limited to symptomatic
treatment; however, the disease continues to progress with
accumulation of significant disability, worsening quality
of life, reduced productivity, nursing home placement,
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and increased mortality.4 Attempts to slow or modify disease progression in PD have resulted in mixed outcomes
and no treatment has yet to definitively demonstrate disease modification (see Table 1 for recent disease-modifying trials).5–8 Therefore, treatments that slow disease
progression remain a major unmet therapeutic need in
PD.
Isradipine, a dihydropyridine calcium channel antagonist (DHP) that is approved for the treatment of hypertension, is being tested as a potential disease-modifying
intervention in early PD. Isradipine was shown to be neuroprotective in in vitro and in vivo models of parkinsonism.9,10 The mechanism of neuroprotection is linked to
selective vulnerability of substantia nigra pars compacta
neurons that preferentially express L-type calcium channels. Neuroprotective effects of isradipine are achieved at
the plasma concentration that is obtained within the safe
dose range for human administration10,11 and consistent
with the tolerable dosage identified in our phase II study
of isradipine in PD (STEADY-PDII).12 Isradipine is the
most potent of the clinically available Cav1.3 DHPs and
has excellent central nervous system penetration suggesting it is the optimal DHP to target this novel mechanism
of neuroprotection.13,14

Importantly, multiple epidemiological studies have
demonstrated a reduced risk of development of PD in
individuals treated with DHPs compared with other antihypertensive agents15–17 In addition, 4733 hypertensive
individuals with parkinsonism treated with DHPs had a
decreased risk of requiring symptomatic therapy (ST),
admission to a nursing home, and death compared with
those treated with other antihypertensive agents.18
Although select epidemiological studies have failed to
demonstrate this effect, these studies have been limited by
small sample sizes and nonrepresentative cohorts.19,20
Therefore, convergent data from in vivo, in vitro, and
epidemiological studies strongly support the potential
ability of isradipine to slow progression of disability in
PD; representing the strongest preclinical and clinical
rationale of any past or current putative disease-modifying agent for PD.
In addition to sufficient preclinical and early clinical
data, it is critical to use a trial design and outcomes that
will be sensitive to clinically meaningful impacts of an
intervention above and beyond current ST. Most previous
trials (Table 1) have used designs that rely on assessments
prior to the initiation of ST or have used the time to initiation of ST as the primary outcome. These studies may

Table 1. Representative Phase III disease-modifying trials in Parkinson disease.
Trial

Intervention

N

Design

PD population

Duration

Primary outcome(s)

Results

DATATOP Deprenyl and
centertocopherol

800 2 9 2
Early untreated 24 months Time to development of disability
factorial
requiring levodopa therapy

PRECEPT

806 Parallel
group

Early untreated 24 months Time to development of disability
requiring dopaminergic
therapy

600 Parallel
group

Early untreated 16 months UPDRS change

Terminated for prespecified
futility

Early untreated 18 months 1) Superiority of UPDRS change
in early start to placebo
between weeks 12–36
2) Superiority of UPDRS change
in early start to delayed start
between baseline and week 72
3) Noninferiority of early to
delayed start in rate of UPDRS
change between weeks 48-72
Early stable
60 months Global statistical test defined by
treatment
5 outcome measures:
Modified Rankin Scale, Symbol
Digit Modalities Test, PDQ-39
Summary Index, Schwab and
England Activities of Daily
Living scale, and ambulatory
capacity (UPDRS)

1 mg/day but not
2 mg/day met all
criteria for efficacy

QE3

ADAGIO

LS1

CEP-1347
10 mg BID
25 mg BID
50 mg BID
Coenzyme Q10
1200 mg/day
2400 mg/day
Rasagiline
1 mg/day
2 mg/day

Creatine

1176 Delayed
start

1741 Parallel
group

Deprenyl resulted in
reduced hazard of requiring
levodopa therapy
Terminated early for
futility

Terminated due to futility
in an interim analysis of 955
subjects followed up for
5 years
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be affected by differential drop out and differential use of
symptomatic therapies and relatively short duration of
follow-up.
STEADY-PDIII (clinicaltrials.gov NCT02168842) is a
36–month, parallel group, double-blind, placebo-controlled trial that will evaluate the effect of isradipine on
the progression of PD disability in untreated individuals
with early PD.

Methods
Trial design
STEADY-PD III is an ongoing 36-month, double-blind,
randomized, placebo-controlled study of isradipine in 336
participants with early PD at baseline not receiving or
requiring ST (Fig. 1). This design will test the hypothesis
that individuals treated with isradipine will have slower
progression of PD disability as determined by the change
in the total Unified Parkinson Disease Rating Scale
(UPDRS) score21 in the active treatment arm versus placebo between baseline and 36 months. Eligible participants are randomized to isradipine 5 mg twice daily or
matching placebo. Participants are titrated to the treatment dosage over a period of 4–12 weeks and then followed prospectively and systematically during a
maintenance period over the remaining 36 months followed by a 3-day titration off the study drug and 2 week
post-titration safety visit. Temporary study drug suspensions are allowed at the discretion of the investigator and
participants who permanently discontinue the study drug
are encouraged to remain in the study.

K. M. Biglan et al.

investigators committed to the cooperative planning,
implementation, analysis, and reporting of controlled
clinical trials and other research in PD and has successfully completed over 35 multi-center cooperative therapeutic studies including STEADY-PDII.

Participants
Eligible participants have early idiopathic PD (presence of
two out of three cardinal manifestations of PD)22; Age
greater than or equal to 30 years at the time of diagnosis;
Hoehn and Yahr stage23 less than or equal to 2; Diagnosis
of PD less than 3 years, currently NOT receiving ST
(levodopa, dopamine agonist or MAO-B inhibitors) and
NOT projected to require ST for at least 3 months from
the baseline visit. Use of amantadine and/or anticholinergics is allowed at stable dosages prior to enrollment. The
key exclusion criteria include a diagnosis of an atypical
parkinsonism; prior exposure to ST, history of orthostatic
hypotension (based on standard definitions), bradycardia,
congestive heart failure or other cardiac and other systemic diseases, abnormalities on the screening laboratories
or ECG that might preclude safe participation in the
study; presence of cognitive dysfunction defined by a
Montreal Cognitive assessment (MOCA)(104) score <
26;24 clinically significant depression as determined by a
Beck Depression Inventory II (BDI-II) score > 15.25 Participants may take up to two other antihypertensives with
the exception of calcium channel blockers which are
exclusionary.
In addition, participants must meet blood pressure criteria during home blood pressure monitoring prior to
initiating study drug.26

Setting
The study is being conducted at 57 Parkinson Study
Group (PSG) sites in North America and is funded by
the National Institute of Neurological Disorders and
Stroke (NINDS) and the Michael J. Fox Foundation. The
PSG is an independent consortium of scientific

Figure 1. Phase III Study Design.
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Outcome measures
Figure 2 outlines the primary and major secondary outcomes in this study.
The primary outcome is the change in total UPDRS
(sum of mental, ADL and motor components) from baseline to 36 months in the medications “ON” state approximately 1 h after dose of ST for those receiving
symptomatic treatment. The UPDRS is a valid and reliable measure of PD disability that has been effectively
used in a number of PD trials.21,27,28
Key secondary outcomes of clinical importance have
been identified and include: (1) Time to initiation of ST
has been used as a primary outcome measure in several
previous studies of putative disease-modifying agents5,29
and reflects progression early in disease not obscured by
symptomatic therapy; (2) Time to and severity of motor
complications may reflect a secondary measure of progression once type of initial symptomatic treatment is

ª 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

K. M. Biglan et al.

Figure 2. Overview of Efficacy Analyses. Primary outcomes – change
in UPDRS from baseline to 36 months. A-change in UPDRS prior to
initiation of dopaminergic therapy (DT). B-change in UPDRS due to ST
initiation. C-time to initiation of ST. D-trajectory of UPDRS change
over time.

accounted for30,31; (3) A potential beneficial effect of
isradipine on disease progression could be masked by differential usage of ST. To account for this factor, we will
evaluate differential use of ST by calculating the levodopa
equivalent dosages between treatment groups32; (4) Incidence and severity of nonmotor symptoms, as these contribute disproportionately to quality of life and reflect
clinically relevant outcomes in PD.33–35
A variety of exploratory outcome measures will be evaluated including global measures of functional disability
measured by the modified Rankin scale,36 quality of life
measured by PDQ-3937 and NeuroQOL,38 the change in
the ambulatory capacity (sum of 5 UPDRS items: falling,
freezing, walking, gait, postural stability)39, and cognitive
function as measured by MOCA.24 Finally, we will model
the trajectory of UPDRS change before and after initiation of ST (D in Fig. 2).
Plasma pharmacokinetic (PK) samples will be collected
at the screening, 3 month and 6 month visits. The objective of collecting blood PK samples is to confirm isradipine trough concentrations and to establish a sparse PK
profile of isradipine in this population. In addition, blood
samples to extract DNA will be collected at screening and
plasma will be collected at screening and at the end of
the study and stored for future unspecified research.

Statistical analyses
Efficacy analyses will use the intent-to-treat principle. The
primary analysis will compare the active treatment group
(all participants randomized to receive active isradipine)

Isradipine in Early PD

with the placebo group. All P-values for efficacy outcomes
will be two-sided.
The primary analysis will use analysis of covariance
applied to the change from baseline in the total UPDRS
score. The baseline value will also be entered into the
model as a continuous variable, the assigned treatment
and enrolling site will be entered as categorical variables.
A two-tailed test with a = 0.05 will be used to declare statistical significance.
Secondary efficacy analyses of continuous outcome
measures will be performed similar to the primary analysis. The time to initiation of ST and the time to onset of
motor complications will be analyzed using Kaplan–Meier
plots and Cox Regression.
Supplementary analyses of the final study outcomes will
be conducted with current use of symptomatic medication (levodopa equivalents) added as an additional predictor variable. The purpose of this analysis is to assess
whether any differences seen in the primary outcome
variable could be attributed to differential use of ST
between the treatment groups. We aim to demonstrate
that at 36 months participants on isradipine will have less
functional decline than participants on placebo, without
requiring more ST. We will also perform exploratory
analyses of the primary outcome, using quantitative modeling along the lines suggested by Holford and Nutt,40
which permits exploration of both short-term symptomatic effects and long-term disease-modifying effects of
treatment in order to further evaluate the differential
impact of isradipine and ST.
Recognizing that the study does not have high power
to detect treatment effects among subgroups, we will conduct exploratory analyses to check the consistency of
treatment effects on the primary and secondary efficacy
measures in relation to selected baseline characteristics,
including gender and race/ethnicity.

Power and sample size considerations
Previous studies29,30,41 support a standard deviation of
12.0 units for the change in the primary outcome, total
UPDRS from baseline to 36 months. The same data suggest an average change in total UPDRS of around 4.0
points over this same time period. However, this change
is deceiving, as the change would likely be much greater
in the absence of symptomatic treatment. If we assume
that treatment with levodopa or a dopaminergic agonist
provides a “bonus” of 12 points, then the underlying true
decline in function over this period would be approximately 16 points, a value broadly consistent with the rate
of change in total UPDRS in participants prior to treatment. We have chosen to power our study to detect a 4point effect, representing an overall 25% reduction in the
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underlying rate of progression. Using the above assumptions, a two-sided test with a = 0.05 and b = 0.8
and making allowance for 15% dropouts, the required
sample size is 168 participants per group or a total 336
participants.
We are also sufficiently powered to address our key
secondary outcomes. Given the sample size above, we will
be able to detect a 29% reduction in the risk of initiating
ST; a reduction of 40% in the risk of developing motor
complications; an approximately 25% reduction in the
dosage of ST; and an effect size of 1.5 points on the nonmotor experiences of daily living between treatment
groups.

Interim analyses
An interim analysis for futility and efficacy will be performed after primary outcome data are available for the
first 168 participants (50%) to enroll. The study will be
terminated for futility if the interim analysis shows that
the conditional power of rejecting the null hypothesis
in favor of a beneficial effect of isradipine is lower than
20% under any scenario that is consistent with the data
accrued at that time. A two-sided P-value in favor of
isradipine of less than 0.001 will be required to stop
for efficacy at the interim analysis. The stringent alpha
level for efficacy was chosen so as to have minimal
effect on the final P-value, should the study run to
completion. In addressing futility, the DSMB will
examine a range of possible treatment effects consistent
with the data obtained in the study at the time of
analysis.

Results
Enrollment of the 336 participants began in November
2014 and was completed in October 2015 at 55 of the 57
active PSG sites. The final subject is expected to complete
the study in November 2018. Baseline characteristics of
the enrolled cohort are detailed in Table 2. At the time of
this report, 330 participants remain active in the study
with 322 participants on active drug.

Discussion
STEADY-PDIII is a novel PD disease-modifying trial evaluating efficacy of isradipine compared with placebo over
36 months. Several novel aspects of study design can be
highlighted. It is the longest duration disease modifying
trial ever conducted in de novo PD. In addition, the primary outcome (UPDRS change in the practically defined
ON state) is powered to detect a 25% slowing of functional decline with isradipine above the benefit from ST,
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Table 2. Baseline characteristics of the enrolled cohort.
Enrolled cohort (n = 336)
Age
Male gender, n (%)
White, non-Hispanic, n (%)
Years from diagnosis
Hoehn and Yahr Stage
Schwab and England ADL score
Total UPDRS
Mental UPDRS
ADL UPDRS
Motor UPDRS
MDS-UPDRS Total
MoCA
Amantadine use at baseline, n (%)
Anticholinergic use at baseline, n (%)

Value1
61.9
230
300
0.9
1.7
94.0
23.1
0.7
5.2
17.2
32.4
28.1
20
5

(9.0)
(68.5)
(89.3)
(0.7)
(0.5)
(7.9)
(8.6)
(1.1)
(3.1)
(7.0)
(11.6)
(1.4)
(6.0)
(1.5)

ADL, activities of daily living; UPDRS, Unified Parkinson Disease Rating
Scale; MDS, Movement Disorders Society; MoCA, Montreal Cognitive
Assessment.
1
Values represent mean (standard deviation) unless otherwise specified.

a difference that would be sufficient to influence clinical
practice and may suggest the likelihood of longer term
benefit. Finally, we are looking at a variety of relevant
motor and nonmotor outcomes that will serve to support
the effect of isradipine on outcomes that are clinically relevant to patients and clinicians.
PD is a slowly progressive neurodegenerative disease.
Most of the previously conducted disease-modifying studies enrolled participants with newly diagnosed PD not yet
requiring ST and followed them for a relatively short period of time (12–24 months) assuming that if benefit is
shown it will persist long term.42 In case the participant
required initiation of ST, the last observation prior to
symptomatic treatment was carried forward. Such design
is driven by lack of objective biomarkers of PD progression and the significant impact of ST on standard clinical
outcome measures. However, this design is artificial and
does not address “real life scenarios” where all patients
are ultimately treated with ST. Indeed, on average 50% of
de novo PD patients initiate ST within 1 year43 with
nearly 100% requiring therapy by 3 years.44,45 If the effect
of isradipine on progression influences the rates of initiation of therapy, then we will be able to evaluate this
through our key secondary outcome measures looking at
time to initiation of ST and differential use of ST. Even
if an intervention is effective early in the course of the
disease, it remains to be proven that the benefit will persist longer term and specifically after initiation of ST.
The interpretation of previous disease-modifying
therapies has been obscured by this lack of long-term
follow-up.
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STEADY-PDIII attempts to address these limitations
through 36-month follow-up of a randomized and
blinded cohort. At 36 months, nearly all participants are
expected to be treated with symptomatic therapies; therefore, this study is powered to demonstrate a disease-modifying effect, if such exists, “on top of” the symptomatic
benefit of existing treatments, making the results more
clinically relevant and reflecting a “real life scenario” in a
relatively small cohort of patients. Although we recognize
that 36 months is not a substantially long period to see
the emergences of long-term complications such as postural instability and dementia, it is the longest duration ever
proposed for a study in a de novo untreated PD population and is likely long enough to provide insight into the
effect of isradipine on relevant motor and nonmotor outcomes. It is also a practically feasible time to maximize
participant retention. Thus, the study design is novel in
that it allows us to take advantage of a relatively small
cohort to address the longer duration benefits of isradipine on top of the benefit derived from ST and to address
clinically relevant longer duration motor and nonmotor
outcomes.
We considered alternative study designs including a
“simple long duration study” design (LS-1), but this
design would require in excess of 1500 participants and
7–8 years to complete.39 Another design used in PD neuroprotective trials is the delayed-start design.7 The arguments against a delayed-start design are the lack of
demonstrable symptomatic benefit of isradipine, the
requirement of >1000 participants for sufficient power,
and controversy on its ability to demonstrate disease modification in PD. Another consideration would be to enroll
individuals at the time of initiation of symptomatic therapy (e.g., CALM-PD),30 however, this would not allow us
to evaluate the impact of isradipine on progression early
in disease not confounded by symptomatic therapy, would
not allow us to assess the impact of isradipine on the timing of initiation of ST and would be unlikely to add value
as both scenarios would assess baseline UPDRS prior to
the initiation of symptomatic therapy. In addition, enrolling participants as early as possible in the disease process
would allow us to maximize the neuroprotective benefit of
isradipine if such an effect exists. We also considered a
prolonged wash out at the end of study or at the time of
initiation of ST to reassess for the evidence of symptomatic benefit, but there are strong arguments against
such design, including lack of obvious symptomatic effect
of isradipine in our Phase II STEADY-PD2 study and participant burden. In addition, there is no consensus regarding the necessary duration of the washout that would be
required for isradipine.5,28 Therefore, our design represents the most rational approach to study the efficacy of
isradipine on disability in PD.

Isradipine in Early PD

Our primary outcome is the change in UPDRS in the
practically defined “ON” state from baseline to
36 months. Despite its limitations, UPDRS remains the
best characterized outcome measure in PD and motor
UPDRS correlates with neuronal loss in the substantia
nigra.46 In addition, substantial data exist on the rate of
change in the UPDRS in the de novo PD population and
on the clinical meaningfulness of this outcome to allow
us to adequately power this study. We have chosen to
evaluate UPDRS in the medication “ON” state once ST is
initiated, which will allow us to identify the benefit of
isradipine “on top of” the benefit conferred by ST, an
outcome with “real world” relevance to patients and clinicians. We have carefully considered UPDRS “OFF” as an
alternative primary outcome. While it may be argued that
the “OFF” assessment is a better representation of
dopaminergic deficit this is not supported by the clinical
data (31–33).47–49 Both levodopa and dopamine agonists
have shown long duration effects on UPDRS lasting days
and even weeks, so that traditional 12 h off medication
assessment does not reflect true dopaminergic deficiency.
Despite these limitations, we recognize the potential value
of “OFF” assessments and the motor UPDRS will be
assessed as an exploratory outcome in the defined medication “OFF” state (at least 12 h after last dose of ST)
once ST has been initiated.
In addition, we have identified a number of key secondary outcomes to corroborate the findings from the
primary analysis. These outcomes include time to initiation of ST, time to the development of motor complications, use of ST and nonmotor disability. Time to
initiation of ST has been a primary outcome in several
completed studies that examined the efficacy of putative
disease-modifying interventions.5,29 Although it has been
criticized for the subjective nature of the measure and
being impacted by the change in the treatment algorithms
that overall lead to the earlier initiation of ST, nevertheless it can be considered a surrogate measure of the disease progression and allows us to compare our findings
with previous trials. The differential use of ST has the
potential to obscure the results and may represent a surrogate of disease severity. For instance, individuals with
greater progression may be on higher dosages of ST
which may offset the benefit of slower progression as
measured by the UPDRS. Not only will this serve as a
surrogate of disease progression and severity, it will allow
us to conduct exploratory analyses accounting for ST
effects.
The development of motor complications represents a
significant milestone in PD progression and results in
impaired quality of life, function, and social isolation.50
Therapies aimed at preventing or ameliorating motor
complications represent a major unmet therapeutic need
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in PD. If isradipine only resulted in a difference in the
rate of motor complications, this would represent a clinically meaningful outcome that would likely influence care.
Nonmotor symptoms can be challenging to treat and
have a disproportionate impact on quality of life.51–53
Therefore, therapy that influences these outcomes will
likely have a significant impact on PD quality of life. The
MDS-UPDRS evaluated a variety of nonmotor outcomes
not assessed in the traditional UPDRS. STEADY-PD III
represents the first interventional trial in de novo population to systematically evaluate the MDS-UPDRS and will
allow for further validation of this scale. We have chosen
not to use it as the primary outcome as there were limited data on the change in MDS-UPDRS in de novo PD
to power the study. We have also chosen a number of
exploratory measures that take advantage of the longer
duration of follow-up in this study compared with previous de novo studies and represent clinically valuable and
complementary outcomes in PD. These measures represent components of the NINDS Common Data Elements
and have largely been validated in PD and include measures of function, quality of life, gait, and cognition.
The study design has some limitations. A biomarker to
validate target engagement of isradipine at the CAV1.3
channel does not exist and therefore a negative study may
reflect a failure of target engagement. We have considered
collecting biomarkers of oxidative stress and mitochondrial function as potential down steam effects of isradipine but these would only be indirect measures and have
not been validated with isradipine in in vivo or in vitro
models. We are collecting DNA and plasma for future
analyses of novel biomarkers that may assist in interpretation of the study. We will analyze PK data to ensure that
a minimum concentration necessary for neuroprotection
is achieved and to address whether variability in clinical
response is related to variations in serum concentrations.
A final limitation is that participants are enrolled based
on the clinical diagnosis of PD, raising the possibility that
approximately 10% of participants might not have a
presynaptic dopaminergic deficit. The use of DAT scan at
enrollment could obviate this concern but would be associated with increased costs and time and would not
definitively exclude individuals without PD. All investigators are credentialed by the PSG, experienced in the diagnosis and care of PD and the conduct of PD-related trials
and therefore, we anticipate a low false-positive diagnosis
rate. Regardless, we are collecting data on the change in
diagnosis and will conduct post hoc analyses that incorporate this information.
In conclusion, this study is testing isradipine as a
potential novel neuroprotective agent in PD based on
robust preclinical and strong epidemiological data. The
STEADY-PDIII study design is unique in assessing the
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impact of isradipine over 36 months, at a time point
where all participants will likely be on ST allowing us to
determine if the benefit is sustained “on top of” traditional ST. In addition, the study design allows us to
determine if the effects on motor function are corroborated by important secondary outcomes assessing clinically relevant measures of ST use, motor complications,
nonmotor function, global disability, quality of life,
ambulatory capacity, and cognition. This design is novel
and innovative and allows for the determination of longer
duration benefits on several clinically relevant outcomes
in a relatively small cohort on top of the benefit derived
from ST.
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